199 related articles for article (PubMed ID: 30590695)
1. Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases.
Wijetilleka S; Jayne DR; Mukhtyar C; Ala A; Bright PD; Chinoy H; Harper L; Kazmi MA; Kiani-Alikhan S; Li CK; Misbah SA; Oni L; Price-Kuehne FE; Salama AD; Workman S; Wrench D; Karim MY
Rheumatology (Oxford); 2019 May; 58(5):889-896. PubMed ID: 30590695
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.
Wijetilleka S; Mukhtyar C; Jayne D; Ala A; Bright P; Chinoy H; Harper L; Kazmi M; Kiani-Alikhan S; Li C; Misbah S; Oni L; Price-Kuehne F; Salama A; Workman S; Wrench D; Karim MY
Autoimmun Rev; 2019 May; 18(5):535-541. PubMed ID: 30844552
[TBL] [Abstract][Full Text] [Related]
3. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.
van Assen S; Agmon-Levin N; Elkayam O; Cervera R; Doran MF; Dougados M; Emery P; Geborek P; Ioannidis JP; Jayne DR; Kallenberg CG; Müller-Ladner U; Shoenfeld Y; Stojanovich L; Valesini G; Wulffraat NM; Bijl M
Ann Rheum Dis; 2011 Mar; 70(3):414-22. PubMed ID: 21131643
[TBL] [Abstract][Full Text] [Related]
4. Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases.
Guerrini G; Franzetti F; Giacomelli R; Meroni L; Riva A; Scirè CA; Scrivo R; Tavio M; Agostinone A; Airò P; Atzeni F; Bartalesi F; Bazzichi L; Berardicurti O; Cassola G; Castagna A; Castelli F; Cattelan A; Citriniti G; Cristini F; De Rosa F; Fracassi E; Galloway J; La Paglia GMC; Moioli MC; Ripamonti D; Saracino A; Tani C; Tascini C; Tieghi T; Tinelli M; Zabotti A; Sarzi-Puttini P; Galli M
Clin Exp Rheumatol; 2020; 38(2):245-256. PubMed ID: 31498077
[TBL] [Abstract][Full Text] [Related]
5. Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening).
Cuadros EN; Calzada-Hernández J; Clemente D; Martín SG; Silveira LF; Lirola-Cruz MJ; Tagarro A; Lovillo MC; Rueda RMA; López AL; Aritziturri MS; Calvo C
Eur J Pediatr; 2022 Jun; 181(6):2343-2354. PubMed ID: 35258699
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
Guerry MJ; Brogan P; Bruce IN; D'Cruz DP; Harper L; Luqmani R; Pusey CD; Salama AD; Scott DG; Savage CO; Watts RA; Jayne DR
Rheumatology (Oxford); 2012 Apr; 51(4):634-43. PubMed ID: 21613248
[TBL] [Abstract][Full Text] [Related]
7. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.
Marco H; Smith RM; Jones RB; Guerry MJ; Catapano F; Burns S; Chaudhry AN; Smith KG; Jayne DR
BMC Musculoskelet Disord; 2014 May; 15():178. PubMed ID: 24884562
[TBL] [Abstract][Full Text] [Related]
8. New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases.
Ong MS; Rothman D; Barmettler S; Son MB; Lo M; Roberts J; Natter M
Rheumatology (Oxford); 2022 Apr; 61(4):1610-1620. PubMed ID: 34329428
[TBL] [Abstract][Full Text] [Related]
9. EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021.
Jansen MHA; Rondaan C; Legger GE; Minden K; Uziel Y; Toplak N; Maritsi D; van den Berg L; Berbers GAM; Bruijning P; Egert Y; Normand C; Bijl M; Foster HE; Koné-Paut I; Wouters C; Ravelli A; Elkayam O; Wulffraat NM; Heijstek MW
Ann Rheum Dis; 2023 Jan; 82(1):35-47. PubMed ID: 35725297
[TBL] [Abstract][Full Text] [Related]
10. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2.
Curtis JR; Johnson SR; Anthony DD; Arasaratnam RJ; Baden LR; Bass AR; Calabrese C; Gravallese EM; Harpaz R; Kroger A; Sadun RE; Turner AS; Williams EA; Mikuls TR
Arthritis Rheumatol; 2021 Aug; 73(8):e30-e45. PubMed ID: 34128356
[TBL] [Abstract][Full Text] [Related]
11. Position statement on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies, part 3: precautions in situations of surgery, fever, and opportunistic infections.
Clemente D; Cuadros EN; Lovillo MC; Hernández JC; Martín SG; Silveira LF; Cruz MJL; Tagarro A; Rueda RMA; López López A; Aritziturri MS; Calvo C
Eur J Pediatr; 2024 Feb; 183(2):915-927. PubMed ID: 38047962
[TBL] [Abstract][Full Text] [Related]
12. B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.
Md Yusof MY; Vital EM; Buch MH
Curr Rheumatol Rep; 2015 Oct; 17(10):65. PubMed ID: 26290110
[TBL] [Abstract][Full Text] [Related]
13. British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy.
Grigoriadou S; Clubbe R; Garcez T; Huissoon A; Grosse-Kreul D; Jolles S; Henderson K; Edmonds J; Lowe D; Bethune C
Clin Exp Immunol; 2022 Oct; 210(1):1-13. PubMed ID: 35924867
[TBL] [Abstract][Full Text] [Related]
14. Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases.
Wijetilleka S; Jayne D; Mukhtyar C; Karim MY
Lupus Sci Med; 2019; 6(1):e000337. PubMed ID: 31413852
[TBL] [Abstract][Full Text] [Related]
15. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases.
Duru N; van der Goes MC; Jacobs JW; Andrews T; Boers M; Buttgereit F; Caeyers N; Cutolo M; Halliday S; Da Silva JA; Kirwan JR; Ray D; Rovensky J; Severijns G; Westhovens R; Bijlsma JW
Ann Rheum Dis; 2013 Dec; 72(12):1905-13. PubMed ID: 23873876
[TBL] [Abstract][Full Text] [Related]
16. Current perspective on rituximab in rheumatic diseases.
Schioppo T; Ingegnoli F
Drug Des Devel Ther; 2017; 11():2891-2904. PubMed ID: 29042750
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study.
Padoan R; Felicetti M; Gatto M; Polito P; Doria A; Schiavon F
Clin Exp Rheumatol; 2020; 38 Suppl 124(2):188-194. PubMed ID: 32441645
[TBL] [Abstract][Full Text] [Related]
18. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes.
Makatsori M; Kiani-Alikhan S; Manson AL; Verma N; Leandro M; Gurugama NP; Longhurst HJ; Grigoriadou S; Buckland M; Kanfer E; Hanson S; Ibrahim MA; Grimbacher B; Chee R; Seneviratne SL
QJM; 2014 Oct; 107(10):821-8. PubMed ID: 24778295
[TBL] [Abstract][Full Text] [Related]
19. Consensus of the Spanish society of pediatric rheumatology for transition management from pediatric to adult care in rheumatic patients with childhood onset.
Calvo I; Antón J; Bustabad S; Camacho M; de Inocencio J; Gamir ML; Graña J; La Cruz L; Robledillo JC; Medrano M; Merino R; Modesto C; Nuñez E; Rua MJ; Torrente-Segarra V; Vargas C; Carmona L; Loza E
Rheumatol Int; 2015 Oct; 35(10):1615-24. PubMed ID: 25917856
[TBL] [Abstract][Full Text] [Related]
20. Standardization of red flags for referral to rheumatologists and ophthalmologists in patients with rheumatic diseases and ocular involvement: a consensus statement.
Olivieri I; Accorinti M; Abicca I; Bisceglia P; Cimino L; Latanza L; Leccese P; Lubrano E; Marchesoni A; Miserocchi E; Neri P; Salvarani C; Scarpa R; D'Angelo S;
Rheumatol Int; 2018 Sep; 38(9):1727-1734. PubMed ID: 29961101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
